nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

13.07.2020 | short review

San Antonio Breast Cancer Symposium 2019: human epidermal growth factor receptor 2(HER2)-positive breast cancer and image-guided biopsy to detect pathologic complete response (pCR)

verfasst von: Clemens Dormann, M.D.

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Summary

At the 2019 San Antonio Breast Cancer Symposium, new data on the management of heavily pretreated human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer were discussed. The phase 3 HER2CLIMB and the phase 2 DESTINY-Breast01 trials investigating tucatinib and trastuzumab deruxtecan, respectively, have met their primary endpoints.

In an early disease setting, four studies investigated whether image-guided biopsies could identify patients with a pathologic complete response (pCR) to neoadjuvant chemotherapy, thus allowing safe omission of surgery. As residual disease was missed in a significant number of cases, these trials could not confirm data from smaller previous studies.

Vorheriger Artikel Four lines of immunochemotherapy combinations in a young patient with an aggressive metastatic colorectal cancer

Nächster Artikel Treatment options in early triple-negative breast cancer

Cardoso F, Senkus E, Costa A, et al. 4th ESO—ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29(8):1634–57. https://doi.org/10.1093/annonc/mdy192.CrossRefPubMed

Giordano SH, Temin S, Chandarlapaty S, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2—positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;14(8):501–4. https://doi.org/10.1200/JOP.18.00290.CrossRef

Moulder SL, Borges VF, Baetz T, et al. Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2+-advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer (MBC). Clin Cancer Res. 2017;23(14):3529–36. https://doi.org/10.1158/1078-0432.CCR-16-1496.CrossRefPubMed

Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res. 2009;69:1795.

Murthy R, Borges VF, Conlin A, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:880–8. https://doi.org/10.1016/S1470-2045(18)30256-0.CrossRefPubMed

Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609. https://doi.org/10.1056/NEJMoa1914609.CrossRefPubMed

Doi T, Shitara K, Naito Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18(11):1512–22. https://doi.org/10.1016/S1470-2045(17)30604-6.CrossRefPubMed

Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T‑DM1. Clin Cancer Res. 2016;22(20):5097–108. https://doi.org/10.1158/1078-0432.CCR-15-2822.CrossRefPubMed

Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039–46. https://doi.org/10.1111/cas.12966.CrossRefPubMedPubMedCentral

10.

Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–21. https://doi.org/10.1056/NEJMoa1914510.CrossRefPubMed

11.

Hennigs A, Riedel F, Marmé F, et al. Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Res Treat. 2016;160(3):491–9. https://doi.org/10.1007/s10549-016-4016-4.CrossRefPubMedPubMedCentral

12.

Heil J, Kuerer HM, Pfob A, et al. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol. 2020;31(1):61–71. https://doi.org/10.1016/j.annonc.2019.10.012.CrossRefPubMed

13.

van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neo-adjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630–40. https://doi.org/10.1016/S1470-2045(18)30570-9.CrossRefPubMed

14.

Santonja A, Sánchez-Muñoz A, Lluch A, et al. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018;9(41):26406–16. https://doi.org/10.18632/oncotarget.25413.CrossRefPubMedPubMedCentral

15.

Kuerer HM, Vrancken Peeters MTFD, Rea DW, et al. Nonoperative management for invasive breast cancer after neoadjuvant systemic therapy: conceptual basis and fundamental international feasibility clinical trials. Ann Surg Oncol. 2017;24(10):2855–62. https://doi.org/10.1245/s10434-017-5926-z.CrossRefPubMed

16.

van la Parra RF, Kuerer HM. Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Res. 2016;18(1):28. https://doi.org/10.1186/s13058-016-0684-6.CrossRef

17.

Schaefgen B, Mati M, Sinn HP, et al. Can routine imaging after neoadjuvant chemotherapy in breast cancer predict pathologic complete response? Ann Surg Oncol. 2016;23(3):789–95. https://doi.org/10.1245/s10434-015-4918-0.CrossRefPubMed

18.

Peintinger F, Kuerer HM, Anderson K, et al. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol. 2006;13(11):1443–9. https://doi.org/10.1245/s10434-006-9086-9.CrossRefPubMed

19.

De Los Santos JF, Cantor A, Amos KD, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational breast cancer research consortium trial 017. Cancer. 2013;119(10):1776–83. https://doi.org/10.1002/cncr.27995.CrossRefPubMedPubMedCentral

20.

Marinovich ML, Houssami N, Macaskill P, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst. 2013;105(5):321–33. https://doi.org/10.1093/jnci/djs528.CrossRefPubMed

21.

Heil J, Pfob A, Sinn HP, et al. Diagnosing residual disease and pathologic complete response after neoadjuvant chemotherapy in breast cancer patients by image-guided vacuum-assisted breast biopsy: results of a prospective multicenter trial. Cancer Res. 2020; https://doi.org/10.1158/1538-7445.SABCS19-GS5-03.CrossRef

22.

Heil J, Sinn P, Richter H, et al. RESPONDER—diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast cancer—a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial. BMC. Cancer. 2018;18(1):851. https://doi.org/10.1186/s12885-018-4760-4.CrossRefPubMed

23.

Tasoulis MK, Lee HB, Yang W, et al. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: a multi-institutional pooled analysis. Cancer Res. 2020; https://doi.org/10.1158/1538-7445.SABCS19-GS5-04.CrossRef

24.

Basik M, Cecchini RS, De Los Santos JF, et al. Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery. Cancer Res. 2020; https://doi.org/10.1158/1538-7445.SABCS19-GS5-05.CrossRef

25.

Vrancken Peeters MTFD, Loevezijn A, van der Noordaa MEM, et al. Towards omitting breast surgery in patients with a pathologic complete response after neoadjuvant systemic treatment: interim analysis of the MICRA trial (minimally invasive complete response assessment). Cancer Res. 2020; https://doi.org/10.1158/1538-7445.SABCS19-GS5-06.CrossRef

26.

van der Noordaa MEM, van Duijnhoven FH, Loo CE, et al. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: study design and feasibility of the MICRA trial (minimally invasive complete response assessment). Breast. 2018;40:76–81. https://doi.org/10.1016/j.breast.2018.04.015.CrossRefPubMed

Titel: San Antonio Breast Cancer Symposium 2019: human epidermal growth factor receptor 2(HER2)-positive breast cancer and image-guided biopsy to detect pathologic complete response (pCR)
verfasst von: Clemens Dormann, M.D.
Publikationsdatum: 13.07.2020
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-020-00632-x

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

The therapeutic landscape of advanced melanoma

Circulating tumour DNA-guided adjuvant chemotherapy in colorectal carcinoma

Four lines of immunochemotherapy combinations in a young patient with an aggressive metastatic colorectal cancer

ASH highlights 2019: “aggressive B-cell lymphoma”

Neoadjuvant chemoradiotherapy in rectal cancer

Chemoradiotherapy alone or chemoradiotherapy followed by surgery in rectal cancer